At June 30, 2024 the Company had cash and cash equivalents of $19.4 million, as compared to $23.0 million, as of March 31, 2024. The Company believes it has sufficient cash to support operations into the second calendar quarter of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACST:
- Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
- Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
- Acasti Pharma achieves 50% enrollment in STRIVE-ON safety trial
- Acasti Announces Year-End 2024 Financial Results, Provides Business Update
- Acasti Pharma sees cash runway into 2Q26